H1 profitability largely met expectations; however, the mid-term guidance downgrade was disappointing
29/07/26 -"bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth drivers. Management has reaffirmed its 2026 ..."
Pages
66
Language
English
Published on
29/07/26
You may also be interested by these reports :
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...
24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...